Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study. (2021)
Attributed to:
AGILE: Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment
funded by
COVID
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1093/jac/dkab318
PubMed Identifier: 34450619
Publication URI: http://europepmc.org/abstract/MED/34450619
Type: Journal Article/Review
Volume: 76
Parent Publication: The Journal of antimicrobial chemotherapy
Issue: 12
ISSN: 0305-7453